Regeneron has agreed to lower drug prices for some Americans as part of a deal with the Trump administration, which aims to link U.S. drug prices to the lowest prices in other developed countries. The company will also provide its newly approved gene therapy for hearing loss, Otarmeni, for free to eligible U.S. patients. This gene therapy, approved by the FDA under a priority program, treats a rare genetic condition causing deafness and marks a breakthrough for patients who previously relied on cochlear implants. Regeneron's pricing concessions are part of a broader effort by the Trump administration to make medicines more affordable while exempting companies from tariffs for three years.
